Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)


Riechelmann R. P. , Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., ...More

CLINICAL COLORECTAL CANCER, vol.18, no.3, pp.183-194, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.1016/j.clcc.2019.05.003
  • Title of Journal : CLINICAL COLORECTAL CANCER
  • Page Numbers: pp.183-194

Abstract

This study evaluated safety and quality of life in patients with metastatic colorectal cancer undergoing treatment with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan). Most patients treated with this combination experienced either improvement or stability in quality of life scores. Aflibercept plus FOLFIRI is tolerable in the treatment of patients with metastatic colorectal cancer with a safety profile similar to that seen in previous studies of these individual medications.